CHDI
Listed here are over 980 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Wijeratne PA, Johnson EB, Eshaghi A, Aksman L, Gregory S, Johnson HJ, Poudel GR, Mohan A, Sampaio C, Georgiou-Karistianis N, Paulsen JS, Tabrizi SJ, Scahill RI, IMAGE-HD, PREDICT-HD and TRACK-HD investigators, Alexander DC
Robust markers and sample sizes for multicenter trials of Huntington disease
Ellis N, Tee A, McAllister B, Massey T, McLauchlan D, Stone T, Correia K, Loupe J, Kim KH, Barker D, Hong EP, Chao MJ, Long JD, Lucente D, Vonsattel JPG, Pinto RM, Elneel KA, Ramos EM, Mysore JS, Gillis T, Wheeler VC, Medway C, Hall L, Kwak S, Sampaio C, Ciosi M, Maxwell A, Chatzi A, Monckton DG, Orth M, Landwehrmeyer GB, Paulsen JS, Shoulson I, Myers RH, van Duijn E, Rickards H, …Holmans P
Genetic risk underlying psychiatric and cognitive symptoms in Huntington's disease
Alexander B, Georgiou-Karistianis N, Beare R, Ahveninen LM, Lorenzetti V, Stout JC, Glikmann-Johnston Y
Accuracy of automated amygdala MRI segmentation approaches in Huntington's disease in the IMAGE-HD cohort
Julayanont P, Heilman KM, McFarland NR
Early-motor phenotype relates to neuropsychiatric and cognitive disorders in Huntington's disease
Furlong LS, Jakabek D, Power BD, Owens-Walton C, Wilkes FA, Walterfang M, Velakoulis D, Egan G, Looi JC, Georgiou-Karistianis N
Morphometric in vivo evidence of thalamic atrophy correlated with cognitive and motor dysfunction in Huntington's disease: The IMAGE-HD stud
Psychiatry Res Neuroimaging
April 30, 2020
298 :111048
298 :111048
PMID: 32120305
Di Marco A, Vignone D, Gonzalez Paz O, Fini I, Battista MR, Cellucci A, Bracacel E, Auciello G, Veneziano M, Khetarpal V, Rose M, Rosa A, Gloaguen I, Monteagudo E, Herbst T, Dominguez C, Muñoz-Sanjuán I
Establishment of an in vitro human blood-brain barrier model derived from induced pluripotent stem cells and comparison to a porcine cell-based system
Ontoria JM, Biancofiore I, Fezzardi P, Ferrigno F, Torrente E, Colarusso S, Bianchi E, Andreini M, Patsilinakos A, Kempf G, Augustin M, Steinbacher S, Summa V, Pacifici R, Muñoz-Sanjuan I, Park L, Bresciani A, Dominguez C, Sherman LT, Harper S
Combined peptide and small-molecule approach toward nonacidic THIQ inhibitors of the KEAP1/NRF2 interaction
Bertoglio D, Verhaeghe J, Korat Š, Miranda A, Cybulska K, Wyffels L, Stroobants S, Mrzljak L, Dominguez C, Skinbjerg M, Liu L, Munoz-Sanjuan I, Staelens S
Elevated type 1 metabotropic glutamate receptor availability in a mouse model of Huntington's disease: a longitudinal PET study
Chongtham A, Bornemann DJ, Barbaro BA, Lukacsovich T, Agrawal N, Syed A, Worthge S, Purcell J, Burke J, Chin TM, Marsh JL
Effects of flanking sequences and cellular context on subcellular behavior and pathology of mutant HTT
Dvorzhak A, Grantyn R
Single synapse indicators of glutamate release and uptake in acute brain slices from normal and Huntington mice
Smith-Geater C, Hernandez SJ, Lim RG, Adam M, Wu J, Stocksdale JT, Wassie BT, Gold MP, Wang KQ, Miramontes R, Kopan L, Orellana I, Joy S, Kemp PJ, Allen ND, Fraenkel E, Thompson LM
Aberrant development corrected in adult-onset Huntington's disease iPSC-derived neuronal cultures via WNT signaling modulation
Morton AJ, Middleton B, Rudiger S, Bawden CS, Kuchel TR, Skene DJ
Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): Compensatory neuroprotection in a neurodegenerative disease?
Mégret L, Nair SS, Dancourt J, Aaronson J, Rosinski J, Neri C
Combining feature selection and shape analysis uncovers precise rules for miRNA regulation in Huntington's disease mice
Andrews SC, Langbehn DR, Craufurd D, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Stout JC, TRACK-HD Investigators
Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease
Ghavami A, Olsen M, Kwan M, Beltran J, Shea J, Ramboz S, Duan W, Lavery D, Howland D, Park LC
Transcriptional assessment of striatal mRNAs as valid biomarkers of disease progression in three mouse models of Huntington's disease
Messer A, Butler DC
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders
McAdam RL, Morton A, Gordon SL, Alterman JF, Khvorova A, Cousin MA, Smillie KJ
Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt (Q140/Q140) mouse model of Huntington's disease
Carlozzi NE, Boileau NR, Chou KL, Ready RE, Cella D, McCormack MK, Miner JA, Dayalu P
HDQLIFE and neuro-QoL physical function measures: Responsiveness in persons with Huntington's disease
Batista AR, King OD, Reardon CP, Davis C, Shankaracharya, Philip V, Gray-Edwards H, Aronin N, Lutz C, Landers J, Sena-Esteves M
Ly6a differential expression in blood-brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B.
Polosecki P, Castro E, Rish I, Pustina D, Warner JH, Wood A, Sampaio C, Cecchi GA
Resting-state connectivity stratifies premanifest Huntington's disease by longitudinal cognitive decline rate
Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, Nag S, Warner JH, Landwehrmeyer B, Al-Tawil N, Halldin C, Forsberg A, Ware J, Dilda V, Wood A, Sampaio C, Varrone A, PEARL-HD and LONGPDE10 collaborators
PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progression
Kedaigle AJ, Reidling JC, Lim RG, Adam M, Wu J, Wassie B, Stocksdale JT, Casale MS, Fraenkel E, Thompson LM
Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice
Julayanont P, McFarland NR, Heilman KM
Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence
Cariulo C, Verani M, Martufi P, Ingenito R, Finotto M, Deguire SM, Lavery DJ, Toledo-Sherman L, Lee R, Doherty EM, Vogt TF, Dominguez C, Lashuel HA, Petricca L, Caricasole A
Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13
Biochem Biophys Res Commun
January 15, 2020
521 (3) :549-554
521 (3) :549-554
PMID: 31677786
Pflanz CP, Charquero-Ballester M, Majid DSA, Winkler AM, Vallée E, Aron AR, Jenkinson M, Douaud G
One-year changes in brain microstructure differentiate preclinical Huntington's disease stages
Bigan E, Sasidharan Nair S, Lejeune FX, Fragnaud H, Parmentier F, Mégret L, Verny M, Aaronson J, Rosinski J, Neri C
Genetic cooperativity in multi-layer networks implicates cell survival and senescence in the striatum of Huntington's disease mice synchronous to symptoms
Zlebnik NE, Gildish I, Sesia T, Fitoussi A, Cole EA, Carson BP, Cachope R, Cheer JF
Motivational impairment is accompanied by corticoaccumbal dysfunction in the BACHD-Tg5 rat model of Huntington's disease
Aviolat H, Pinto RM, Godschall E, Murtha R, Richey HE, Sapp E, Vodicka P, Wheeler VC, Kegel-Gleason KB, DiFiglia M
Assessing average somatic CAG repeat instability at the protein level
Chandra A, Valkimadi PE, Pagano G, Cousins O, Dervenoulas G, Politis M, Alzheimer’s Disease Neuroimaging Initiative
Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
Ardan T, Baxa M, Levinská B, Sedláčková M, Nguyen TD, Klíma J, Juhás Š, Juhásová J, Šmatlíková P, Vochozková P, Motlík J, Ellederová Z
Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration
Dis Model Mech
December 12, 2019
13 (2) :dmm041319
13 (2) :dmm041319
PMID: 31645369
PMCID: PMC6918760
DOI: 10.1242/dmm.041319
Ouk K, Aungier J, Ware M, Morton AJ
Abnormal photic entrainment to phase-delaying stimuli in the R6/2 mouse model of Huntington's disease, despite retinal responsiveness to light
Estrada-Sánchez AM, Blake CL, Barton SJ, Howe AG, Rebec GV
Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice
Smarr B, Cutler T, Loh DH, Kudo T, Kuljis D, Kriegsfeld L, Ghiani CA, Colwell CS
Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis
Carlozzi NE, Schilling SG, Boileau NR, Chou KL, Perlmutter JS, Frank S, McCormack MK, Stout JC, Paulsen JS, Lai JS, Dayalu P
How different aspects of motor dysfunction influence day-to-day function in Huntington's disease
Papadopoulou AS, Gomez-Paredes C, Mason MA, Taxy BA, Howland D, Bates GP
Extensive expression analysis of Htt transcripts in brain regions from the zQ175 HD mouse model using a QuantiGene multiplex assay
Irvine EE, Katsouri L, Plattner F, Al-Qassab H, Al-Nackkash R, Bates GP, Withers DJ
Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease
Marottoli FM, Priego M, Flores-Barrera E, Pisharody R, Zaldua S, Fan KD, Ekkurthi GK, Brady ST, Morfini GA, Tseng KY, Tai LM
EGF treatment improves motor behavior and cortical GABAergic function in the R6/2 mouse model of Huntington's disease
Gregory S, Odish OFF, Mayer I, Mills J, Johnson EB, Scahill RI, Rothwell J, Rees G, Long JD, Tabrizi SJ, Roos RAC, Orth M
Multimodal characterization of the visual network in Huntington's disease gene carriers
Clin Neurophysiol
November 1, 2019
130 (11) :2053-2059
130 (11) :2053-2059
PMID: 31541982
Ciosi M, Maxwell A, Cumming SA, Hensman Moss DJ, Alshammari AM, Flower MD, Durr A, Leavitt BR, Roos RAC, TRACK-HD team, Enroll-HD team Holmans P, Jones L, Langbehn DR, Kwak S, Tabrizi SJ, Monckton DG
A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes
Diaz-Castro B, Gangwani MR, Yu X, Coppola G, Khakh BS
Astrocyte molecular signatures in Huntington's disease